NCT00120757

Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)

Efficacy of Alendronate Versus Placebo in the Treatment of HIV-1 Associated Osteoporosis, a Multicenter, Randomized, Controlled Trial. ANRS 120 Fosivir

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 140 (planned)
• Sponsor: French National Agency for Research on AIDS and Viral Hepatitis · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Osteopenia and osteoporosis are being described more frequently in people with HIV infection. This study will test the efficacy of alendronate in comparison with a placebo after 2 years, in people with primary osteoporosis. People will receive the recommended adequate intake of calcium and vitamin D.

Detailed description

The purposes of this trial are: * To study the efficacy of alendronate in HIV-associated osteoporosis * To measure the prevalence of osteoporosis in HIV patients and to detect risk factors in a large cohort of HIV patients from the screening phase

Conditions

• Osteoporosis
• HIV Infections

Interventions

Type	Name	Description
DRUG	Alendronate

Timeline

• Start date: 2004-10-01
• Primary completion: 2008-11-01
• Completion: 2008-11-01
• First posted: 2005-07-19
• Last updated: 2026-04-03

Locations

3 sites across 1 country: France